132 related articles for article (PubMed ID: 15790432)
21. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
[TBL] [Abstract][Full Text] [Related]
22. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
23. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors.
Jarzabek K; Koda M; Kozlowski L; Mittre H; Sulkowski S; Kottler ML; Wolczynski S
Eur J Cancer; 2005 Dec; 41(18):2924-34. PubMed ID: 16289616
[TBL] [Abstract][Full Text] [Related]
24. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
25. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
26. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
[TBL] [Abstract][Full Text] [Related]
27. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Lee P; Rosen DG; Zhu C; Silva EG; Liu J
Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
[TBL] [Abstract][Full Text] [Related]
28. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
29. Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?
Noruzinia M; Coupier I; Pujol P
Cancer; 2005 Oct; 104(8):1567-74. PubMed ID: 16155942
[TBL] [Abstract][Full Text] [Related]
30. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
31. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia.
Villavicencio A; Bacallao K; Avellaira C; Gabler F; Fuentes A; Vega M
Gynecol Oncol; 2006 Oct; 103(1):307-14. PubMed ID: 16677694
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Wang M; Pan JY; Song GR; Chen HB; An LJ; Qu SX
Eur J Surg Oncol; 2007 Mar; 33(2):195-201. PubMed ID: 17046193
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
34. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
[TBL] [Abstract][Full Text] [Related]
35. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
[TBL] [Abstract][Full Text] [Related]
36. Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E; Benítez J; Palacios J
Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
[TBL] [Abstract][Full Text] [Related]
37. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and progesterone receptors in ovarian epithelial tumors.
Lindgren PR; Cajander S; Bäckström T; Gustafsson JA; Mäkelä S; Olofsson JI
Mol Cell Endocrinol; 2004 Jun; 221(1-2):97-104. PubMed ID: 15223136
[TBL] [Abstract][Full Text] [Related]
39. Detection of mRNA levels for the estrogen alpha, estrogen beta and androgen nuclear receptor genes in archival breast cancer tissue.
Smith RA; Lea RA; Weinstein SR; Griffiths LR
Cancer Lett; 2006 Jun; 237(2):248-55. PubMed ID: 16046054
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer.
Borgquist S; Holm C; Stendahl M; Anagnostaki L; Landberg G; Jirström K
J Clin Pathol; 2008 Feb; 61(2):197-203. PubMed ID: 18223096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
